NewAmsterdam Net Debt To E B I T D A from 2010 to 2025
| NAMS Stock | 23.49 0.21 0.89% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 1.73 | Current Value 1.65 | Quarterly Volatility 33.10603901 |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 32.6 K, Net Interest Income of 4.1 M or Interest Income of 13.6 M, as well as many indicators such as Price To Sales Ratio of 67.95, Dividend Yield of 0.0 or PTB Ratio of 3.01. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Net Debt To E B I T D A |
Latest NewAmsterdam Pharma's Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of NewAmsterdam Pharma over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). NewAmsterdam Pharma's Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
NewAmsterdam Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 8.23 | |
| Coefficient Of Variation | 402.33 | |
| Mean Deviation | 15.51 | |
| Median | (0.70) | |
| Standard Deviation | 33.11 | |
| Sample Variance | 1,096 | |
| Range | 133 | |
| R-Value | 0.28 | |
| Mean Square Error | 1,084 | |
| R-Squared | 0.08 | |
| Significance | 0.30 | |
| Slope | 1.93 | |
| Total Sum of Squares | 16,440 |
NewAmsterdam Net Debt To E B I T D A History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 1.73 | 1.65 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.